In 2001, Hainan Sihuan Pharmaceutical Co., Ltd. was founded, marking the starting point of the entrepreneurial development of Sihuan Pharmaceutical Holdings Group. At its start stage, Sihuan Pharmaceutical attached great importance to marketing. Later, with the establishment of Hainan Sihuan Cardio-Cerebral Vascular Drug Research Institute, it is able to make progress both in market development and new product R&D, thus facilitating the company to develop rapidly. Later, through capital operation such as merger and acquisition, it further improved its industrial chain by successively incorporating Beijing Sihuan Pharmaceutical, Shenzhen Sihuan Pharmaceutical and other companies into Sihuan Pharmaceutical, developing into a pharmaceutical group with integrated R&D, production and sales capabilities.
Sihuan Pharmaceutical Holdings Group was incorporated in Bermuda in April 2006, and was successfully listed in Singapore in March 2007. In 2009, in order to meet the needs of greater development, Sihuan Pharmaceutical Holdings Group completed privatization and was delisted from Singapore, and was successfully re-listed in Hong Kong in 2010.
Up to now, Sihuan Pharmaceutical Holdings Group has developed into a pharmaceutical enterprise with strong R&D capabilities, high-quality product structure, and sound production management system. Together with a unique marketing model and professional services, it deeply engages in the cardio-cerebral vascular drug industry in China to serve human health, winning wide acclaim from the community and users, and has established an unique brand image of “Sihuan”.